On September 18, 2025, Jasper Therapeutics, Inc. announced an underwritten public offering of 11.67 million shares of its common stock at $2.43 per share, aiming to raise approximately $30 million for development programs. This event is significant as it supports ongoing clinical research and expansion efforts.